Anavex Life Sciences Corp. AVXL
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a CNS/neurology/psychiatry drug developer. Its lead program, ANAVEX 2-73 (blarcamesine), is in Phase 1 for Early Alzheimer's disease; Rett syndrome; Fragile X syndrome. Its next catalyst on record is blarcamesine (ANAVEX 2-73): Anavex has an FDA meeting scheduled for November to discuss adding pediatric participants to the Phase 3 Rett syndrome study. (November 2026).
Upcoming catalysts
- November 2026blarcamesine (ANAVEX 2-73) — Anavex has an FDA meeting scheduled for November to discuss adding pediatric participants to the Phase 3 Rett syndrome study.
the FDA granted the Company a meeting to discuss adding pediatric participants to the Phase 3 protocol for November.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ANAVEX 2-73 (blarcamesine) | Early Alzheimer's disease (AD IND submitted Mar 2026; ADME and DDI clinical pharmacology studies underway; Phase 3 design to be agreed with FDA) | small molecule | Phase 1 |
| ANAVEX 2-73 (blarcamesine) | Rett syndrome (Phase 3 ANAVEX2-73-RS-005, ~170 pts, not yet initiated) | small molecule | Phase 1 |
| ANAVEX 3-71 | Frontotemporal dementia / schizophrenia (Phase 1 FTD; development paused) | small molecule | Phase 1 |
| ANAVEX 2-73 (blarcamesine) | Fragile X syndrome (IND planned Sept 2026) | small molecule | Pre-clinical |
| ANAVEX 1-41 | Neurodegenerative disease (paused) | small molecule | Pre-clinical |
| ANAVEX 1066 | Neuropathic and visceral pain (paused) | small molecule | Pre-clinical |
Recent results and decisions
- Oct 20, 2026positive DDI study fully enrolled with 65 healthy volunteers on 30 mg blarcamesine; clinical conduct complete, no serious adverse events on preliminary observation.
Based on preliminary observations, no serious adverse events were reported.
Filing - Oct 15, 2026n/a FDA cleared the IND for blarcamesine in Fragile X syndrome, allowing a planned Phase 2a study (~60 adult males) to proceed.
today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the Company may proceed with its planned clinical study under its Investigational New Drug Application (IND)
Filing - Oct 15, 2026completed enrollment Anavex completed clinical conduct of ADME study with 8 participants receiving 30 mg blarcamesine, with no serious adverse events reported based on preliminary observations.
The last participant completed the study in mid-October, concluding clinical conduct.
Filing
6 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.